Moringa: The 15% CAGR ingredient with the thinnest evidence in the top 50

Moringa is the fastest-growing botanical market (14.9% CAGR, $1.6B) but has only 20 clinical trials. Compare this with for example curcumin that has 200+ trials for a $93M market. Moringa sells almost entirely on nutritional profile claims, not mechanisms. The first company to map moringa's isothiocyanate (moringin) mechanism and patent the Nrf2 activation pathway owns the scientific story for a $6.6B projected market.Publications of interest:https://pubmed.ncbi.nlm.nih.gov/30783799/https://pubmed.ncbi.nlm.nih.gov/25808883/https://pmc.ncbi.nlm.nih.gov/articles/PMC9916933/